Sarepta Therapeutics (SRPT) shares fell more than 10% in Friday premarket trading after Europe's drug regulator recommended the refusal of marketing authorization for the company's Duchenne muscular dystrophy drug Elevidys.
Sarepta's partner outside the US, Roche said it will continue discussions with the European Medicines Agency to explore a potential way forward.
Roche said the benefit-risk profile of Elevidys remains positive for the ambulatory patient population.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.